Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1177331 | 0.83 | HRH3 (0.71) | HRH3 | |
| SCHEMBL3384995 | 0.78 | HRH3 (1.00) | HRH3KMT2AALDH1A1HPGDTSHR | |
| SCHEMBL3383089 | 0.74 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3380536 | 0.73 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3382809 | 0.72 | HRH3 (1.00) | HRH3 | |
| SCHEMBL3382379 | 0.72 | HRH3 (1.00) | HRH3KMT2A | |
| SCHEMBL8281593 | 0.72 | HRH3 (0.56) | HRH3 | |
| SCHEMBL3383368 | 0.71 | HRH3 (0.56) | HRH3ALDH1A1 | |
| SCHEMBL3383396 | 0.70 | HRH3 (0.79) | HRH3ALDH1A1 | |
| SCHEMBL1177297 | 0.69 | HRH3 (0.57) | HRH3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | claimed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | claimed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | claimed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| EP-1771432-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-04-11 | — | — | EP | disclosed |
| WO-2005096734-A2 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | HRH3 1/4885KMT2A 160/4885NPC1 1370/4885 |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | HRH3 1/4885KMT2A 160/4885NPC1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.